Zobrazeno 1 - 10
of 2 440
pro vyhledávání: '"HER2-Positive breast cancer"'
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 845-853 (2024)
Feng Zhao,1 Hongzhen Zhang2 1The First Hospital of Anhui University of Science and Technology, Huainan, Anhui, People’s Republic of China; 2Anhui University of Science and Technology, Huainan, Anhui, People’s Republic of ChinaCorrespondence: Hong
Externí odkaz:
https://doaj.org/article/3973a57306414a0b8b53871e21ac2d33
Autor:
Ran Ran, Shidi Zhao, Yan Zhou, Xinyue Hang, Hui Wang, Yuan Fan, Yusi Zhang, Yifan Qiao, Jin Yang, Danfeng Dong
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-17 (2024)
Abstract Background Different hormone receptor (HR) expression patterns have significant biological and therapeutic implications in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the distinction between
Externí odkaz:
https://doaj.org/article/c62db2b92ea6485b8eea8eb9f1be7b12
Autor:
Mingxia Jiang, Yue Chai, Jiaxuan Liu, Maiyue He, Yipeng Wang, Xue Yang, Zeyu Xing, Mengqi Zhang, Shihan Zhou, Fei Ma, Jiayu Wang, Peng Yuan, Binghe Xu, Qiao Li
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Inetetamab is the first domestically developed innovative anti-HER2 monoclonal antibody in China, proven effective and safe in HER2-positive advanced breast cancer. However, its efficacy and safety in neoadjuvant treatment of HER2
Externí odkaz:
https://doaj.org/article/32387e293c134642a179a5d28b93fb22
Publikováno v:
Heliyon, Vol 10, Iss 23, Pp e39545- (2024)
Aims: Adenosine metabolism in the breast cancer microenvironment is critical for tumor immunity. However, the prognostic significance of adenosine in breast cancer remains unclear. We aimed to dynamically monitor serum adenosine levels in patients wi
Externí odkaz:
https://doaj.org/article/20e0cc4f120c423b883e5fb78d94c165
Autor:
Xing Liu, Wenwen Shen
Publikováno v:
International Journal of Pharmaceutics: X, Vol 8, Iss , Pp 100302- (2024)
In this study, the trastuzumab-functionalized SK-BR-3 cell membrane-wrapped mesoporous silica nanoparticles loaded with pyrotinib (Tra-CM-MSN-PYR) were prepared for targeted therapy of HER2-positive breast cancer. Transmission electron microscopy (TE
Externí odkaz:
https://doaj.org/article/a4a88fc8ea844d1c953cc0146d36a0e2
Autor:
Shuning Liu, Bo Lan, Yuanyi Wang, Tao Yang, Lixi Li, Hewei Ge, Cheng Zeng, Binghe Xu, Haili Qian, Fei Ma
Publikováno v:
EBioMedicine, Vol 109, Iss , Pp 105379- (2024)
Summary: Background: The PHILA study suggests that pyrotinib, trastuzumab, and docetaxel significantly improved progression-free survival (PFS) compared with placebo, trastuzumab, and docetaxel in patients with untreated HER2-positive metastatic brea
Externí odkaz:
https://doaj.org/article/9bb421ef3cf74b95b5cb31e0773cfbb1
Publikováno v:
Journal of Pharmaceutical Analysis, Vol 14, Iss 10, Pp 100977- (2024)
Trastuzumab has improved survival rates in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), but drug resistance leads to treatment failure. Natural killer (NK) cell-mediated antibody-dependent cell cytotoxicity (ADCC) repr
Externí odkaz:
https://doaj.org/article/6b3649ef1f604c7da224a314d7c2ae85
Autor:
Lin Yang, Songhao Chen, Meixue Wang, Shujia Peng, Huadong Zhao, Ping Yang, Guoqiang Bao, Xianli He
Publikováno v:
Heliyon, Vol 10, Iss 19, Pp e38221- (2024)
Despite the approval of several therapeutic agents for HER2-positive breast cancer, drug resistance remains a significant challenge, hindering the patient's prognosis. Thus, our study aimed to establish a risk model to predict the prognosis of patien
Externí odkaz:
https://doaj.org/article/89c69c508099462cab292dc9c0190681
Autor:
Qiao Li, Dan Lv, Xiaoying Sun, Mengyuan Wang, Li Cai, Feng Liu, Chenghui Li, Jiuda Zhao, Jing Sun, Yehui Shi, Fei Ma
Publikováno v:
Cancer Innovation, Vol 3, Iss 5, Pp n/a-n/a (2024)
Abstract Background We explored the efficacy and safety of inetetamab combined with sirolimus and chemotherapy for the treatment of human epidermal factor receptor 2 (HER2)‐positive metastatic breast cancer patients with abnormal activation of the
Externí odkaz:
https://doaj.org/article/6cff81cea58240268e3dd6e588e6951c
Autor:
Debora Gagliato, Tomás Reinert, Cláudio Rocha, Monique Tavares, Sâmio Pimentel, William Fuzita, Márcia Araújo, Danielli Matias, Sabina Aleixo, Bruno França, Érida Magaton, Natália Brito, Ana Carolina Cardoso, Vivienne Castilho
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 437-449 (2024)
Abstract Introduction Biological monoclonal antibodies play a pivotal role in cancer treatment, with biosimilars significantly enhancing their accessibility. In Brazil’s ethnically diverse setting, real-world evidence is crucial for assessing the e
Externí odkaz:
https://doaj.org/article/8914f24dcbdd4abc820ddec9d2ad82a2